SY

Smita Yogesh Ghewade

Active Director Director DIN 09526390
DIN 09526390 First appointment Mar 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2022
Shareholding value •••• Premium profile

About Smita Yogesh Ghewade

Data last updated:

Smita Yogesh Ghewade is a Director at Manfred Pharmaceuticals Private Limited (since 2022). The company operates in Pharma. Manfred Pharmaceuticals Private Limited reported revenue of ₹11.5 Lakh (FY 2025).

DIN 09526390
Primary Designation Director
Industry Pharma
First Appointment 05 Mar 2022
Oldest Company Age 15 yrs
Largest company Manfred Pharmaceuticals Private Limited · ₹11.5 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Mar 20222011₹11.5 Lakh (FY 2025)Active

Board colleagues of Smita Yogesh Ghewade

Directorship timeline

Open interactive timeline →
Manfred Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Smita Yogesh Ghewade

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Smita Yogesh Ghewade

Smita Yogesh Ghewade currently holds 1 directorship: Manfred Pharmaceuticals Private Limited (Director, since 05 Mar 2022, revenue ₹11.5 Lakh (FY 2025)).

Smita Yogesh Ghewade was first appointed on 05 Mar 2022 as Director at Manfred Pharmaceuticals Private Limited.

The current boards of Smita Yogesh Ghewade's companies include Yogesh Balavant Ghewade (Manfred Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available